AllVascular announces that it has received CE approval for its proprietary Arterial Access System (AVAS®). The AVAS® device enables safe and repeated access to the arterial circulation which can enable the targeted delivery of therapeutic substances (chemotherapy and immunotherapies) to treat solid tumours within multiple organs. This approval enables the Company to commence sales of the AVAS® into European Union (EU) member countries, Hong Kong, Singapore, Australia and New Zealand upon lodgement of the Certificate with the appropriate regulatory authorities.